Location · Dothan, AL
Clinical trials in Dothan, AL
34 recruiting studies have a site in Dothan, and 1 of them accept healthy volunteers.
34 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 3
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Pfizer
- Location
- Dothan, AL + 111 other US sites
- Eligibility basics
- Ages 0 mo–49
- RecruitingPhase 2/Phase 3
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer
- Location
- Dothan, AL + 58 other US sites
- Eligibility basics
- Ages 35–80
- RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Regeneron Pharmaceuticals
- Location
- Dothan, AL + 41 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population
Jubaan Ltd.
- Location
- Dothan, AL + 7 other US sites
- Eligibility basics
- Ages 45–84
- RecruitingPhase 2
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
AbbVie
- Location
- Dothan, AL + 60 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
Sonavex, Inc.
- Location
- Dothan, AL + 19 other US sites
- Eligibility basics
- Ages 18–84
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche
- Location
- Dothan, AL + 91 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 2
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Chiesi Farmaceutici S.p.A.
- Location
- Dothan, AL + 5 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
- Location
- Dothan, AL + 131 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Regeneron Pharmaceuticals
- Location
- Dothan, AL + 42 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics, Inc
- Location
- Dothan, AL + 130 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Dothan, AL + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Regeneron Pharmaceuticals
- Location
- Dothan, AL + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Dothan, AL + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Dothan, AL + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 4
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Vanda Pharmaceuticals
- Location
- Dothan, AL + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche
- Location
- Dothan, AL + 58 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Dothan, AL + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
AbbVie
- Location
- Dothan, AL + 53 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Dothan, AL + 27 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC
- Location
- Dothan, AL + 35 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Takeda
- Location
- Dothan, AL + 36 other US sites
- Eligibility basics
- Ages 18–65